In Brief: Wyeth-Ayerst's Zosyn
Executive Summary
Wyeth-Ayerst's Zosyn: Piperacillin/tazobactam sodium injection supplemental NDA (50-684/SE-001) approved May 8 for treatment of nosocomial pneumonia. In a 300-patient study, the rate of clinical cure of nosocomial pneumonia was 74% for Zosyn plus tobramycin compared to 50% for ceftazidime plus tobramycin. Recommended Zosyn dose for nosocomial pneumonia is 3.375 g every four hours plus an aminoglycoside...